Main Article Content
The purpose of current study was to compare the reliability of testing and retesting patients with localized prostate cancer with validated tools for assessing the International Prostate Symptom Score (IPSS) and (QOL) in Overactive Bladder men (OAB), to develop and evaluate correlations. Methods:
This study obtain the three dairy and Overactive Bladder Symptom Score (OABSS), the International Prostate Symptom Score (IPSS) and (QOL) over the course of six visits. Utilizing the weighted KABBA coefficient, comparisons were done. OABSS, voiding diary, International Prostate Symptom Score (IPSS) and (QOL) all were compared with internal correlation coefficients (ICC) between the first and second application verified. 3-Day Bladder Diary Questionnaire correlation: Patient perceptions status of bladder, (IPSS) and (QOL) at each visit (6 visits in total) in 52 localized prostate cancer patients. A test was performed, including the index. At enrollment they underwent OABSS and after they received Mirabegron 25 mg once daily for 1 month and then repeated the questionnaire after 6 months. Validity and reliability of patients' OABSS and its correlation with the patients' perception of their 3-day bladder diary and bladder status was performed, respectively. Results: Of the total 52 OAB patient's, 27 had their OAB recorded in the wet and 25 had their OAB recorded in the dry. Weighted KABBA Coe feints ranged from 0.137 to 0.307 for each score of symptoms and 0.233 for the total symptoms score, which was moderate to good. Seventy-two percent of the patients (72%) were followed up and had completed responsiveness studies. During the first month on Mirabegron 25 mg once daily from baseline, OAB symptoms worsen significantly. OABSS gradually deceased over time within three months after retest reliability was confirmed.
OAB in our population is significant in terms of the following, frequency, urge, incontinence, OABSS, (IPSS) and (QOL) improvements. However, the current study shows that Mirabegron is effective in treating other OAB symptoms in patients such as frequent urinary incontinence, urge, OABSS, and the International Prostate Symptom Score, which improves over time was done.
Wolff GF, Kuchel GA, Smith PP (2014) Overactive bladder in the vulnerable elderly. Res Rep Urol 6: 131-38.
Abrams P, Kelleher CJ, Kerr LA, Rogers RG (2000) Overactive bladder significantly affects quality of life Am J Manag Care 6: S580-S590.
Lee YS, Lee KS, Jung JH, Han DH, Oh SJ, et al. (2011) Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. World J Urol 29: 185-190.
Austin PF, Bauer SB, Bower W, Chase J, Franco I (2016) The standardization of terminology of lower urinary tract function: report from the Standardization Sub-Committee of the International Continence Society. Neurourol Urodyn 35: 471-481.
Homma Y, Yamaguchi O, Hayashi K, Neurogenic Bladder Society Committee (2006) Epidemiologic survey of lower urinary tract symptoms in Japan. Urology 68: 560-564.
Homma Y, Kakizaki H, Yamaguchi O, Yamanishi T, Nishizawa O, et al. (2011) Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score. Urology 77: 60-64.
Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynsji T, et al. (2005) Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodynam 24: 215-225.
Irwin DE, Milsom I, HunsKaar S, Reilly K, Kopp Z, et al. (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study Eur Urol 50: 1306-1314.
Eapen RS, Radomski SB (2016) Review of the epidemiology of overactive bladder. Res Rep Urol 8:71-76.
Corcos J, Przydacz M, Campeau L, Gary G, Hickling D, et al. (2017) Appendix: Executive summary of CUA guideline on adult overactive bladder. Can Urol Assoc J 11: E248-E49.
Corcos J, Przydacz M, Campeau L, Gary G, Hickling D, et al. (2017) CUA guideline on adult overactive bladder. Can Urol Assoc J 11: E142-E73.
Hsu FC, Weeks CE, Selph SS, Blazina I, Holmes RS, et al. (2019) Updating the evidence on drugs to treat overactive bladder: A systematic review. Int Urogynecol J 30: 1603-1617.
D'Ancona C, Haylen B, Oelke M, Abranches-Monteiro L, Arnold E, et al. (2019) The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn 38: 433-477.
Sawaqed F, Suoub M (2021) Validating 7-items Overactive Bladder Symptom Score (OABSS) through Arabic linguistic version Sci Rep 11: 661.